Small bowel injuries
Conditions
Interventions
Patients in the treatment group receive rebamipide 300 mg/day for 8 weeks.
Patients in the control group do not receive rebamipide.
Sponsors
Osaka City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The rheumatoid arthritis patients taking loxoprofen more than three months
Exclusion criteria
Exclusion criteria: 1. Dysphagia. 2. Pregnant, possibly pregnant, or lactating women. 3. With intestinal stricture or intestinal fistula, diagnosed by diagnostic image or past clinical inspection. 4. Using cardiac pacemaker or other self-contained medical electronics. 5. The subject of any other clinical test/trial which will affect the results this study. 6. Can not comply with the study requirements or cannot follow instructions for the device. 7. Extensive esophageal hiatal hernia. 8. Life-threatening disorder. 9. Abdominal radiotherapy in past. 10. Do not agree to remove the capsule either by endoscopically or surgically when retention occurred. 11. Allergic or idiosyncratic to the drug. 12. Inadequate to entry judged by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Capsule endoscopic findings (number of ulcers/erosions and red spots) | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom assessment (anemia, melena, complications) | — |
Countries
Japan
Contacts
Public ContactToshio Watanabe
Osaka City University Graduate School of Medicine Department of Gastroenterology
Outcome results
None listed